| Title : Cytochrome P450 inhibitor\/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting - Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| Author(s) : Rimel BJ , Chase DM , Perhanidis J , Ghazarian AA , Du EX , Wang T , Song J , Golembesky AK , Hurteau JA , Kalilani L , Salani R , Monk BJ |
| Ref : Gynecologic Oncology Rep , 51 :101332 , 2024 |
| Abstract : Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| ESTHER : Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| PubMedSearch : Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| PubMedID: 38362364 |
Rimel BJ, Chase DM, Perhanidis J, Ghazarian AA, Du EX, Wang T, Song J, Golembesky AK, Hurteau JA, Kalilani L, Salani R, Monk BJ (2024)
Cytochrome P450 inhibitor\/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting
Gynecologic Oncology Rep
51 :101332
Rimel BJ, Chase DM, Perhanidis J, Ghazarian AA, Du EX, Wang T, Song J, Golembesky AK, Hurteau JA, Kalilani L, Salani R, Monk BJ (2024)
Gynecologic Oncology Rep
51 :101332